United States Patent 10,967,060 Claims Analysis and US Patent Landscape Overview
US Patent 10,967,060 is a granted US patent whose claims and continuation history define the enforceable scope available to the assignee in US infringement and licensing discussions. A complete, claim-by-claim analysis and a mapped landscape of related US filings (continuations, divisionals, continuations-in-part, and major family members) cannot be produced from the information provided in the request alone because the patent’s public text, claim set, prosecution history, assignee, and family identifiers are not included.
What does US 10,967,060 claim in the independent claims?
No claim text has been provided, so the independent claims and their limiting features cannot be extracted, classified, or interpreted.
Which claim elements narrow scope: compounds, compositions, methods, or device features?
Claim-element breakdown requires the actual claim language (e.g., required structural features, functional limitations, process steps, substrate/delivery components, or performance parameters). Without the claims, element-level scoping is not possible.
How are “comprising” and dependent claim fallbacks likely to affect claim breadth?
This requires the dependent claim structure and any claim construction-relevant language, which is not included.
How broad are the dependent claims of US 10,967,060?
Dependent claims require the exact claim set to map fallback positions (e.g., specific embodiments, narrower concentration ranges, particular polymers, defined operating conditions, or defined therapeutic endpoints).
What specific embodiments are protected?
Protected embodiments are claim-specific and cannot be identified without the claim text.
What manufacturing or formulation parameters are locked in?
Formulation and manufacturing limitations require the actual parameter language and definitions.
What is the priority and family structure behind US 10,967,060?
A landscape requires: earliest priority date(s), application number(s), assignee, CPC/IPC classification, and patent family members across jurisdictions. Those are not provided.
What are the US continuations, divisionals, and terminal disclaimers?
This requires the prosecution data for US 10,967,060 (continuation/divisional relationships and any terminal disclaimer entries).
Are there co-pending sibling patents with overlapping disclosure?
Sibling overlap requires access to family members and their claim sets.
When does US 10,967,060 expire and how do regulatory exclusivities affect enforceability?
Expiration and term adjustments require the filed/priority dates and any PTA/PTA values, plus whether any patent is tied to an FDA-regulated product. None of that is available in the request.
What are the statutory expiration dates (including PTA) for US 10,967,060?
PTA requires public prosecution or USPTO term calculation data not included here.
Do patent term adjustments or disclaimers shorten the effective enforcement window?
Requires terminal disclaimer status and PTA records.
What Orange Book status does US 10,967,060 have?
Orange Book listing is product- and NDA/BLA-dependent. Patent-to-product mapping cannot be done without identifying the drug and the Orange Book entries referenced by the patent.
Which NDA/BLA is tied to US 10,967,060?
Not specified.
Is US 10,967,060 listed for method-of-use, formulation, or combination products?
Not specified.
What is the likely litigation risk for US 10,967,060: infringement theories and design-around paths?
Infringement theory depends on the exact claim limitations (and how those map to accused products or processes). Design-around risk analysis depends on the claim structure and any disclaimed scope or prosecution history estoppel.
What infringement theories are strongest: literal infringement vs. doctrine of equivalents?
Requires claim wording and prosecution history.
Which design-around routes are most credible given the claim limitations?
Requires the claim elements and dependent narrowing.
Have there been Paragraph IV challenges involving US 10,967,060?
Paragraph IV outcomes require the linked NDA number and the FDA litigation history for the relevant generic applicant(s). No such identifiers are provided.
Which generic applicants filed Paragraph IV certifications?
Not provided.
What were the settlement dates, triggers, and entry-into-market commitments?
Not provided.
What patent challenges exist against US 10,967,060: IPR, PGR, and district court validity
Validity attack mapping requires PTAB and district court dockets tied to this specific patent, including institution decisions and claim cancellation outcomes. No litigation history is included.
What prior art references are most likely to be used against the claims?
Requires claim scope and the patent’s disclosure and bibliographic data to identify relevant references.
What claim types are most vulnerable: composition vs. method vs. apparatus?
Requires the claim categories.
How strong is the patent estate around US 10,967,060?
Estate strength requires mapping the family and siblings that share similar subject matter: overlapping independent claim coverage, different claim categories, and remaining expiration dates. No family member information is provided.
How many related claims remain enforceable in the same family?
Requires full family data.
Does the estate cover multiple delivery forms, dosing regimens, or process steps?
Requires knowledge of claim variations across family members.
How does US 10,967,060 compare with nearby patents in the same CPC/IPC space?
Comparison requires identifying the relevant technological area from the patent’s classification and claims, then listing competitor patents and their priority timelines. Those inputs are not included.
Which competitor assignees hold overlapping patents?
Not provided.
Are there clear freedom-to-operate gaps created by stronger competitor claims?
Not provided.
Key Takeaways
- A claim-by-claim and landscape analysis of US Patent 10,967,060 cannot be completed from the request as written because the patent’s claim text, assignee, priority data, family members, and any enforcement or regulatory linkages are not included.
- Any attempt to infer scope, expiration, Orange Book status, litigation posture, or generic-entry risk without the underlying patent content would produce non-actionable or incorrect results.
FAQs
-
How can I identify the independent claim limitations of US 10,967,060 without the claim text?
Without the patent’s claim set, the independent claim limitations cannot be reliably extracted or categorized.
-
What determines whether US 10,967,060 is listed in the Orange Book?
Orange Book listing is determined by whether the patent is associated with a specific approved NDA/BLA and is listed for composition, method-of-use, or other qualifying categories.
-
What is the difference between patent term expiration and effective exclusivity windows?
Patent term is governed by filing/priority dates plus adjustments, while exclusivity can extend market protection based on regulatory triggers.
-
Which PTAB proceedings most commonly challenge granted US patents like 10,967,060?
Common challenge formats include IPR (and occasionally PGR) targeting validity, but the relevant docket depends on this patent’s recorded history.
-
How do claim dependencies affect licensing leverage in practice?
Licensing leverage depends on how strong the independent claims are and whether dependent claims provide practical fallback scope, which requires the actual claim structure.
References
- USPTO Patent Full Text and Image Database (for US 10,967,060).
- FDA Orange Book (for NDA/BLA patent listings, if applicable to US 10,967,060).
